Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Montana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 171 | 21% |
| 2020 | 1 | 145 | 22% |
| 2021 | 1 | 176 | 25% |
| 2022 | 2 | 143 | 27% |
| 2023 | 1 | 154 | 30% |
| 2024 | 1 | 133 | 32% |
| 2025 from claims | – | 134 109–158 | 32% |
| 2026 forecast | – | 137 107–172 | 32% |
| 2027 forecast | – | 139 103–184 | 32% |
| 2028 forecast | – | 140 99–194 | 33% |
| 2029 forecast | – | 142 97–204 | 33% |
| 2030 forecast | – | 144 94–213 | 34% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Montana; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 25% inpatient hospital, 75% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 18 | 1,061−2.2%/yr | −2.2%/yr | 0.3 | 0% | 1,120 in 2030+0.8%/yr |
| Washington | 6 | 357−1.8%/yr | −1.8%/yr | 0.5 | 0% | 290 in 2030−3.1%/yr |
| Arizona | 4 | 305−10%/yr | −10%/yr | 0.4 | 0% | 540 in 2030+9.8%/yr |
| Colorado | 5 | 282−2.4%/yr | −2.4%/yr | 0.6 | 14% | 540 in 2030+12%/yr |
| Oregon | 2 | 124−13%/yr | −13%/yr | 0.3 | 0% | 140 in 2030+1.9%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Montana · Every state · Compare with California
Boston Scientific leads with 53% of company spending on these surgeons in 2025, +28 pts on 2024.
In 2025, 5 companies reported engagement with Montana’s surgeons worth $14K in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.